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nruptured, asymptomatic arteriovenous malfor-
mations (AVMs) lurk in the brains of approxi-
mately one person in every thousand; their
prevalence, based on four studies of magnetic resonance
imaging (MRI) of 7,359 people without brain disor-
ders,1-4 was 0.1 % (95% confidence interval [CI] 0% to
0.2%). Some of these brain AVMs may be discovered if
and when they cause intracranial haemorrhage, epilep-
tic seizure(s), headache, or a focal neurological deficit,
but many brain AVMs may potentially lie dormant from
the cradle to the grave.
The detection of this reservoir of unruptured brain
AVMs is likely to depend on the differences in availabil-
ity, uptake, and indications for brain MRI between
countries. Indirect evidence for this comes from the two
ongoing population-based studies of the clinical epi-
demiology of brain AVMs:5,6 in Scotland 54% of all
brain AVMs detected in an incidence study were unrup-
tured at presentation,5 whereas this proportion was 62%
in New York (difference -8%, 95% CI -19% to 4%).6 The
detection rate of unruptured brain AVMs seems set to
rise with the increasing appropriate use of brain MRI
for investigating epilepsy and stroke, as well as more
indiscriminate uses such as ‘health check-ups’ pur-
chased from private health screening companies.7
What’s the prognosis for an adult with an 
unruptured brain AVM?
Only a few published studies are of sufficient quality to
provide reliable estimates of the prognosis for unrup-
tured brain AVMs.8-10 Most cohorts have been small, ret-
rospective, hospital-based, with short incomplete fol-
low-up from an unclear inception point, using un-
blinded assessment according to bespoke rather than
generic outcome measures, without stratification by dif-
ferences in treatment. Even in high quality studies, the
outcome described for unruptured brain AVMs that are
not treated is inevitably biased, since a conservative
strategy may be adopted either because of the ‘untreata-
bility’ of the AVM, or due to the patient’s burden of dis-
ability or co-morbidity.
Nevertheless, some generalisations can be made
about the crude first bleed rate from an unruptured
brain AVM after diagnosis (Table). The most important
elements of brain AVM vascular anatomy (‘angioarchi-
tecture’) for risk stratification are deep venous drainage
(Figure) and location deep within the brain (Table).
An old population-based study found 30-day case
fatality after a bleed to be ~18%,12 which is likely to be
less nowadays, and certainly less than the case fatality
following non-traumatic intracerebral haemorrhage or
aneurysmal subarachnoid haemorrhage.13 Few have esti-
mated the morbidity due to haemorrhage, but it does
seem to vary between studies: by the time of hospital
discharge after a haemorrhage, 33% of patients had a
modified Rankin score ≥3,10 and others found this pro-
portion to decrease to ~5% after ~1 year.14 However, the
Toronto AVM study group found that only 45% of
adults made a recovery from a haemorrhage without a
permanent deficit.15 Although re-bleed rates do not con-
cern us in this article, it is worth mentioning that they
are higher than first bleed rates, and they seem to be
particularly high in the first 6-12 months after a first
bleed,9,10 although the magnitude of the re-bleed rate
varies between studies.10,11,16
Should an adult with an unruptured brain AVM
be treated?
People with brain AVMs are likely to benefit from mul-
tidisciplinary management, although there is consider-
able value from a one-on-one meeting between doctor
and patient. A neuroradiologist, neurosurgeon, radio-
therapist, and clinical nurse specialist should ideally
work with a neurologist with interest and expertise in
the assessment and treatment of seizures, headaches and
chronic disability. A neurologist also has an important
independent role in counselling a patient about the
risks and benefits of various management strategies.
In the absence of controlled studies, the decision to
treat the brain AVM (with any combination of endovas-
cular embolisation, microsurgical removal, and/or
stereotactic radiation therapy) is based on the potential
benefit of treatment reducing the future risk of haemor-
rhage, plus an indirect comparison of the possible risk
of intervention against the presumed risk of future
death/disability if the brain AVM is left untreated.17 This
decision involves the potentially flawed extrapolation of
short-term outcome data to the rest of the patient’s pre-
sumed life expectancy.18,19 Recent research – albeit based
on observational data at a single tertiary referral centre
– leaves many physicians uncertain that treatment does
more good than harm:19,20 interventional treatment of
unruptured brain AVMs was associated with a highly
significant excess of subsequent haemorrhage and dis-
ability at five years in comparison to conservative man-
agement. If these findings and the paucity of controlled
data aren’t enough to support the case for randomisa-
tion, further justification is provided by the likely vari-
ation in treatment practice by personal conviction, local
experience, centre, country, continent, available treat-
ments, and health insurance policy.13,18,19
A Randomised trial of Unruptured Brain AVMs
(ARUBA)
A potential solution to the clinical dilemma posed by an
unruptured brain AVM is randomisation in ARUBA
(www.arubastudy.org). ARUBA is investigating whether
conservative management is superior to interventional
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Subgroup Annual bleed rate
Crude (overall) first bleed rate9,11 ~1%
Exclusive deep venous drainage9 ~2%
Deep brain location9 ~3%
Exclusive deep venous drainage and deep location9 ~8%
Neither deep location nor deep venous drainage9 ~1%
Table: First bleed rates from unruptured brain AVMs
Figure: The vascular anatomy (‘angioarchitecture’) of brain AVMs
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treatment for consenting adults aged ≥18
years, with an unruptured brain AVM that is
potentially treatable, over a minimum follow-
up period of five years, based on outcome
assessments by a neurologist. Although enrol-
ment in this trial may prove challenging
because of the instinctive difficulties some
patients (and doctors) may face in allowing
randomisation to decide whether their ‘time
bomb’ is treated or not, fully informed con-
sent – involving a sanguine discussion of the
risks of intervention – is crucial.
ARUBA is funded by the National Institutes
of Health (ISRCTN 44013133), with per-
patient reimbursement. The trial has ethical
approval in the UK, and a decision about trial
adoption by the UK Stroke Research Network
is pending. Interested investigators should
contact any of the authors, and may also con-
sider participating in a similar trial randomis-
ing people with an unruptured intracranial
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